* If you want to update the article please login/register
Patients with Rheumatoid Arthritis have a different immune system than those who do not have RA.
Source link: https://clinicaltrials.gov/ct2/show/NCT03652961
Chronic pain and exhaustion are common and disabling signs in people with Rheumatoid Arthritis, even in the absence of active inflammation. To determine central pain functions in people with RA, the investigators have developed a short, self-report questionnaire. This research is designed to determine the psychometric properties of CAP-RA and the ability of the questionnaire to predict greater pain in the RA population. The study's secondary objectives include predicting worse fatigue in people with RA, derriving CAP-RA scoring recommendations, investigating other risks associated with persistent RA pain, the relationship between central sensitization and pain, and determining the course of pain and exhaustion in RA. Some participants will finish the CAP-RA questionnaire a week after the baseline visit to determine the questionnaire's test-retest reliability.
Source link: https://clinicaltrials.gov/ct2/show/NCT04515589
The same ultrasound that is used for medical imaging may be used to treat inflammatory disorders such as Rheumatoid Arthritis. Multiple studies in animals with hyper-inflammation conditions and recent human research have found that ultrasound applied to the spleen will reduce blood/genetic markers of inflammation. The MINI ultrasound unit manufactured by SecondWave Systems will be used in this research. With the SecondWave MINI ultrasound unit, an investigational splenic-ultrasound therapy will be delivered. A tiny wearable ultrasound unit is placed over the ribs in the upper left abdomen area for ultrasound stimulation. The spleen and the wearable MINI unit will be located in a safe location around the ribs area by ultrasound imaging technology. In each participant throughout the research, clinical outcome data, patient-reported surveys, and blood draws will be conducted at the five study visits to determine biomarkers of inflammation.
Source link: https://clinicaltrials.gov/ct2/show/NCT05417854
Participants will perform functional MRI following noxious thermal stimulation at post-intervention to determine if the meditation methods differentially influence neural function during noxious thermal stimulation.
Source link: https://clinicaltrials.gov/ct2/show/NCT03975595
RA is a disease in which the immune system attacks the joints, resulting in joint inflammation and swelling in joints, which can be felt by someone with RA as joint pain, stiffness, and swelling. Anti-CCP3 is a self antibody that detects RA and can predict the emergence of RA in the future, particularly if the amount of anti-CCP3 is high. According to the investigators of this report, people with elevations of anti-CCP3 u22652 times the average have about a 50% risk of experiencing RA within three years. This research aims to see if treating HCQ in individuals with elevated levels of anti-CCP3 without joint inflammation can help prevent future onset of RA. Due to elevated titer elevations of anti-CCP3, a 12-month course of HCQ will be required in the prevention of clinically apparent RA at 36 months in patients at high risk of future RA.
Source link: https://clinicaltrials.gov/ct2/show/NCT02603146
Study 1 is a dose finding research that will include a single 89Zr-DFO-CZP PET scan that will take place 24 hours after a single administration of the radiopharmaceutical. To determine the appropriate optimal imaging dose, subsequent groups of two patients will be given 0. 5 mCi decrease or increase dose. Participants will perform four serial whole body PET scans within two hours and 120 hours after receiving the medication.
Source link: https://clinicaltrials.gov/ct2/show/NCT03546335
Although the clinical course of many people with this disorder can mimic that seen in patients with idiopathic pulmonary fibrosis, the true history of fibrotic lung disease associated with rheumatoid arthritis remains largely undefined.
Source link: https://clinicaltrials.gov/ct2/show/NCT00001876
When an interleukin-6 inhibitor is introduced, the researchers will determine if drug metabolism changes in patients with rheumatoid arthritis patients. Patients with rheumatoid arthritis have an elevated level of inflammation in the body, which may lead to reduced production and activity of drug metabolizing enzymes in the liver. Patients with rheumatoid arthritis initiating treatment with an IL-6-receptor inhibitor would eventually have a normalization of the triggered IL-6 pathway that results in increased expression and activity of drug metabolizing enzymes, leading to increased metabolism and increased metabolism. The investigators suspect that patients with a rheumatoid arthritis initiating therapy with an IL-6 receptor inhibitor will result in a normalization of the activated IL-6 pathwayway Patients will ingest a 6-drug mixture consisting of probes for specific CYP enzymes. After three weeks and three months, patients will then begin IL-6 receptor antibody therapy to determine both short- and long-term effects of elevated inflammation.
Source link: https://clinicaltrials.gov/ct2/show/NCT04842981
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions